ClinicalTrials.gg
CompletedNCT01396083COMRADE-CUpdated Sep 27, 2016Results posted

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)

A Phase 3 interventional study of Ranibizumab and Dexamethasone implant and sham injections in Visual Impairment, Macular Edema and Central Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 64 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.

Enrollment
10th of 26
243 · median 178
Started
2011
with 3 others
Phase 3
14 of 26
none open now
Registered
10th of 26
by date
Lead sponsor
20 of 26
Novartis Pharmaceuticals

Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 10th largest by enrollment, is one of 4 that started in 2011, is one of 14 in phase 3, and was the 10th registered.

Vision Disorders

361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.

Browse Vision Disorders studies →

Open to participants now

None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing ranibizumab in Vision Disorders as a file.
02

Study summary

This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator Dexamethasone implant is given once at Month 0 with sham injections PRN afterwards.

03

Conditions studied

  • Visual Impairment
  • Macular Edema
  • Central Retinal Vein Occlusion

Keywords

  • Visual impairment
  • macular edema
  • Central retinal vein occlusion
  • Dexamethasone implant
  • Ranibizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with visual impairment due to macular edema following CRVO
  • Diagnosis of CRVO at maximum 6 months prior to Screening
  • BCVA using ETDRS charts of 20/40 to 20/400 in the study eye

Exclusion criteria

Exclusion Criteria:

  • Media clarity, pupillary dilation and patient cooperation not sufficient for adequate fundus photographs
  • Central retinal thickness (CRT) \< 250 µm in the study eye
  • Prior episode of RVO in the study eye
  • Active formation of new vessels in the study eye
  • Anti-VEGF-treatment in the study or the fellow eye 3 months prior to Baseline
  • IOP ≥ 30mmHg or uncontrolled glaucoma; patients may be re-screened after 1 month if they have undergone glaucoma treatment
  • Improvement of > 10 letters on BCVA between Screening and Baseline

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    Drug: Ranibizumab

  • Active comparator
    Standard of Care

    Drug: Dexamethasone implant and sham injections

Interventions

  • DrugDexamethasone implant and sham injections
06

What researchers measure

Primary outcomes

  1. Mean Average BCVA Change From Month 1 Through Month 6 to Baseline

    the average of the changes in BCVA (letters) from baseline to any post-baseline visit, i.e. the mean of six differences to baseline for the six post-baseline visits at month 1 to 6. BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is pproximately 20/20. An increased score indicates improvement in acuity

    Time frame: Baseline, month 6

Secondary outcomes

  1. Mean BCVA Change at Month 6

    The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors

    Time frame: Baseline, month 6

  2. Number of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the number of participants who gained 15, 10 or 5 more letters of visual acuity at month 6 as compared with baseline

    Time frame: Baseline, 6 month

  3. Time to Achieve a Significant Improvement ≥ 15 Letters

    The time was analyzed by the Kaplan-Maier-Method, adjusting the calculation for dropouts

    Time frame: Baseline, month 6

  4. Change Over Time in BCVA

    The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors

    Time frame: Baseline, month 6

  5. Change Over Time of the Central Retinal Thickness (CRT)

    Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation

    Time frame: Baseline, month 6

  6. Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires

    The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function

    Time frame: Baseline, month 6

  7. Changes in the Quality of Life According to the Short Form (36) Health Survey (SF-36)Questionnaires

    SF-36 summary measures are norm-based scores with mean = 50 and SD = 10. Higher scores indicate better health

    Time frame: Baseline, month 6

  8. Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires

    The EQ-5D visual analog scale ranges from 0 to 100, 0 representing the worst and 100 the best imaginable health state.

    Time frame: Baseline, month 6

  9. Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline

    The proportion of patients with ≥ 10% increase in Internal Ocular Pressure (IOP) compared to baseline at any post-baseline visit.

    Time frame: Baseline, month 6

07

Results

Posted Feb 18, 2015

Participant flow

Participant flow — Overall Study
MilestoneRanibizumabDexamethasone
Started124119
Completed11372
Not completed1147
Withdrew: Adverse event228
Withdrew: Unsatisfactory therapeutic effect213
Withdrew: Consent withdrawn45
Withdrew: Protocol deviation(s)01
Withdrew: Abnormal laboratory value(s)10
Withdrew: Administrative problems10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryMean Average BCVA Change From Month 1 Through Month 6 to Baseline

the average of the changes in BCVA (letters) from baseline to any post-baseline visit, i.e. the mean of six differences to baseline for the six post-baseline visits at month 1 to 6. BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is pproximately 20/20. An increased score indicates improvement in acuity

Time frame:
Baseline, month 6
Reported as:
Mean · Letters
Mean Average BCVA Change From Month 1 Through Month 6 to Baseline
LettersRanibizumabDexamethasone
Mean Average BCVA Change From Month 1 Through Month 6 to Baseline14.6 ± 11.84.8 ± 16.2
SecondaryMean BCVA Change at Month 6

The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors

Time frame:
Baseline, month 6
Reported as:
Least squares mean · Letters
Mean BCVA Change at Month 6
LettersRanibizumabDexamethasone
Mean BCVA Change at Month 614.78 (11.24 to 18.32)-3.17 (-6.80 to 0.46)
SecondaryNumber of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the number of participants who gained 15, 10 or 5 more letters of visual acuity at month 6 as compared with baseline

Time frame:
Baseline, 6 month
Reported as:
Number · Participants
Number of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters
ParticipantsRanibizumabDexamethasone
Gain≥15 letters7322
Loss of ≥15 letters131
Gain ≥10 letters8938
Loss of ≥10 letters435
Gain ≥5 letters10454
Loss of ≥5 letters540
SecondaryTime to Achieve a Significant Improvement ≥ 15 Letters

The time was analyzed by the Kaplan-Maier-Method, adjusting the calculation for dropouts

Time frame:
Baseline, month 6
Reported as:
Median · Time to event (Days)
Time to Achieve a Significant Improvement ≥ 15 Letters
Time to event (Days)RanibizumabDexamethasone
Time to Achieve a Significant Improvement ≥ 15 Letters62 (56 to 91)98 (63 to NA)
SecondaryChange Over Time in BCVA

The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors

Time frame:
Baseline, month 6
Reported as:
Least squares mean · letters
Change Over Time in BCVA
lettersRanibizumabDexamethasone
Month 19.77 (7.27 to 12.27)9.54 (6.98 to 12.10)
Month 212.25 (9.59 to 14.91)11.04 (8.31 to 13.76)
Month 314.04 (10.92 to 17.16)4.99 (1.79 to 8.18)
Month 412.76 (9.48 to 16.04)-1.73 (-5.09 to 1.63)
Month 513.57 (10.25 to 16.89)-2.92 (-6.33 to 0.48)
Month 614.78 (11.24 to 18.32)-3.17 (-6.80 to 0.46)
SecondaryChange Over Time of the Central Retinal Thickness (CRT)

Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation

Time frame:
Baseline, month 6
Reported as:
Mean · µm
Change Over Time of the Central Retinal Thickness (CRT)
µmRanibizumabDexamethasone
Change Over Time of the Central Retinal Thickness (CRT)-376.7 ± 274.9-168.7 ± 288.3
SecondaryChanges in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires

The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function

Time frame:
Baseline, month 6
Reported as:
Mean · Score on a scale
Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires
Score on a scaleRanibizumabDexamethasone
Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires6.0 ± 12.12.0 ± 10.9
SecondaryChanges in the Quality of Life According to the Short Form (36) Health Survey (SF-36)Questionnaires

SF-36 summary measures are norm-based scores with mean = 50 and SD = 10. Higher scores indicate better health

Time frame:
Baseline, month 6
Reported as:
Mean · Units on a scale
Changes in the Quality of Life According to the Short Form (36) Health Survey (SF-36)Questionnaires
Units on a scaleRanibizumabDexamethasone
SF-36 physical component (n=116,113)-0.7 ± 6.30.4 ± 6.6
SF-36 mental component (n=116,113)2.4 ± 8.70.4 ± 9.2
SecondaryChanges in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires

The EQ-5D visual analog scale ranges from 0 to 100, 0 representing the worst and 100 the best imaginable health state.

Time frame:
Baseline, month 6
Reported as:
Mean · Units on a scale
Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires
Units on a scaleRanibizumabDexamethasone
Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires0.1 ± 13.22.0 ± 14.8
SecondaryIncrease Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline

The proportion of patients with ≥ 10% increase in Internal Ocular Pressure (IOP) compared to baseline at any post-baseline visit.

Time frame:
Baseline, month 6
Reported as:
Number · Participants
Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline
ParticipantsRanibizumabDexamethasone
Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline94105

Adverse events

Non-serious events are listed at a 2.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab—10/124 (8.1%)77/124 (62.1%)
Dexamethasone—16/119 (13.4%)99/119 (83.2%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventRanibizumabDexamethasone
IRIS NEOVASCULARISATION (Study eye)Eye disorders0/1244/119
GLAUCOMA (Study eye)Eye disorders0/1243/119
HYPHAEMA (Study eye)Eye disorders0/1243/119
VISUAL ACUITY REDUCED (Study eye)Eye disorders0/1243/119
MACULAR OEDEMA (Study eye)Eye disorders1/1242/119
TRANSIENT ISCHAEMIC ATTACKNervous system disorders0/1242/119
ANGINA PECTORISCardiac disorders0/1241/119
ATRIAL FIBRILLATIONCardiac disorders1/1241/119
CARDIAC FAILURECardiac disorders0/1241/119
MITRAL VALVE INCOMPETENCECardiac disorders0/1241/119
Most frequent other events
Showing 10 of 36
Most frequent other events
EventRanibizumabDexamethasone
INTRAOCULAR PRESSURE INCREASED (Study eye)Investigations7/12438/119
MACULAR OEDEMA (Study eye)Eye disorders13/12419/119
VISUAL ACUITY REDUCED (Study eye)Eye disorders8/12419/119
CONJUNCTIVAL HAEMORRHAGE (Study eye)Eye disorders16/12413/119
OCULAR HYPERAEMIA (Study eye)Eye disorders14/12415/119
EYE PAIN (Study eye)Eye disorders15/12414/119
NASOPHARYNGITISInfections and infestations9/12412/119
VITREOUS FLOATERS (Study eye)Eye disorders5/12411/119
HEADACHENervous system disorders7/12410/119
ABNORMAL SENSATION IN EYE (Study eye)Eye disorders6/1248/119

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RanibizumabDexamethasoneTotal
Mean65.3 ± 11.466.9 ± 12.466.1 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)RanibizumabDexamethasoneTotal
Female524698
Male7273145
08

Study locations

64 sites
  • Novartis Investigative Site
    Augsburg, 85155, Germany
  • Novartis Investigative Site
    Bad Rothenfelde, 49215, Germany
  • Novartis Investigative Site
    Berlin, 10713, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bonn, 53127, Germany
  • Novartis Investigative Site
    Bremen, 28209, Germany
  • Novartis Investigative Site
    Chemnitz, 09116, Germany
  • Novartis Investigative Site
    Darmstadt, 64298, Germany
  • Novartis Investigative Site
    Dortmund, 44137, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Frankfurt, 60318, Germany
  • Novartis Investigative Site
    Freiburg i. Br, 79106, Germany
  • Novartis Investigative Site
    Glauchau, 08371, Germany
  • Novartis Investigative Site
    Göttingen, 37075, Germany
  • Novartis Investigative Site
    Hagen, 58097, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hamburg, 22417, Germany
  • Novartis Investigative Site
    Homburg, 66421, Germany
  • Novartis Investigative Site
    Ingolstadt, 85049, Germany
  • Novartis Investigative Site
    Karlsruhe, 76133, Germany
  • Novartis Investigative Site
    Karlsruhe, 76199, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Koeln, 50935, Germany
  • Novartis Investigative Site
    Lauterbach, 36341, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Ludwigshafen, 67063, Germany
  • Novartis Investigative Site
    Minden, 32427, Germany
  • Novartis Investigative Site
    Muelheim, 45468, Germany
  • Novartis Investigative Site
    Muenster, 48145, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    München, 80336, Germany
  • Novartis Investigative Site
    München, 81675, Germany
  • Novartis Investigative Site
    Nuernberg, 90491, Germany
  • Novartis Investigative Site
    Recklinghausen, 45657, Germany
  • Novartis Investigative Site
    Regensburg, 93042, Germany
  • Novartis Investigative Site
    Sulzbach, 66280, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89075, Germany
  • Novartis Investigative Site
    Wolfsburg, 38442, Germany
  • Novartis Investigative Site
    Würzburg, 97080, Germany
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Budapest, 1133, Hungary
  • Novartis Investigative Site
    Szeged, H-6720, Hungary
  • Novartis Investigative Site
    Bydgoszcz, Poland
  • Novartis Investigative Site
    Bytom, 41-902, Poland
  • Novartis Investigative Site
    Birmingham, B152WB, United Kingdom
  • Novartis Investigative Site
    Birmingham, B18 7QU, United Kingdom
  • Novartis Investigative Site
    Bradford, BD9 6RJ, United Kingdom
  • Novartis Investigative Site
    Cheshire, CW1 4QJ, United Kingdom
  • Novartis Investigative Site
    Colchester, CO3 3NB, United Kingdom
  • Novartis Investigative Site
    Derby, DE22 3NE, United Kingdom
  • Novartis Investigative Site
    Gloucester, GL1 3NN, United Kingdom
  • Novartis Investigative Site
    Guildford, Surrey, GU2 5XX, United Kingdom
  • Novartis Investigative Site
    Kent, CT1 3NG, United Kingdom
  • Novartis Investigative Site
    Leeds, LS9 7TF, United Kingdom
  • Novartis Investigative Site
    London, SE1 7EH, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WH, United Kingdom
  • Novartis Investigative Site
    Middlesborough, TS4 3BW, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG7 2UH, United Kingdom
  • Novartis Investigative Site
    Portsmouth, PO6 3LY, United Kingdom
  • Novartis Investigative Site
    Rugby, CV22 5PX, United Kingdom
  • Novartis Investigative Site
    Westcliff-on-Sea, SS0 0RY, United Kingdom
  • Novartis Investigative Site
    York, YO31 8HE, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2011
First posted
Jul 18, 2011
Start
Aug 2011
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Feb 18, 2015
Last update
Sep 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01396083
Responsible party
Sponsor
First posted
Jul 18, 2011
Start date
Aug 2011
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Feb 18, 2015
Last update
Sep 27, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion